

Pietro A Canetta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7722079/publications.pdf>

Version: 2024-02-01

60
papers

4,369
citations

218592

26
h-index

168321

53
g-index

61
all docs

61
docs citations

61
times ranked

5395
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Predictors and Prognosis of Recurrent IgA Nephropathy in the Kidney Allograft. <i>Glomerular Diseases</i> , 2022, 2, 42-53.	0.2	9
2	A Participant-Centered Approach to Understanding Risks and Benefits of Participation in Research Informed by the Kidney Precision Medicine Project. <i>American Journal of Kidney Diseases</i> , 2022, 80, 132-138.	2.1	3
3	The clinicopathologic spectrum of segmental membranous glomerulopathy. <i>Kidney International</i> , 2021, 99, 247-255.	2.6	30
4	Patient perspectives and involvement in precision medicine research. <i>Kidney International</i> , 2021, 99, 511-514.	2.6	5
5	Rationale and design of the Kidney Precision Medicine Project. <i>Kidney International</i> , 2021, 99, 498-510.	2.6	94
6	Diagnostic Approach to Glomerulonephritis With Fibrillar IgG Deposits and Light Chain Restriction. <i>Kidney International Reports</i> , 2021, 6, 936-945.	0.4	14
7	Late Relapses of Membranous Nephropathy: A Case Series. <i>Kidney360</i> , 2021, 2, 974-982.	0.9	0
8	Concurrent Anti-“Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series. <i>American Journal of Kidney Diseases</i> , 2021, 78, 219-225.e1.	2.1	16
9	Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. <i>Kidney International</i> , 2021, 100, 440-446.	2.6	17
10	Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis. <i>Kidney International</i> , 2021, 100, 672-683.	2.6	21
11	Longitudinal Outcomes of COVID-19-Associated Collapsing Glomerulopathy and Other Podocytopathies. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2958-2969.	3.0	31
12	An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression. <i>Kidney International Reports</i> , 2020, 5, 58-65.	0.4	17
13	Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study. <i>Kidney International</i> , 2020, 97, 10-13.	2.6	23
14	Systematic Review and Meta-Analysis of Native Kidney Biopsy Complications. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1595-1602.	2.2	103
15	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. <i>Kidney International Reports</i> , 2020, 5, 1679-1689.	0.4	17
16	Toward a Clearer Picture of IgA Nephropathy in Spondyloarthritis. <i>Kidney International Reports</i> , 2020, 5, 766-768.	0.4	1
17	Kidney Biopsy Findings in Patients with COVID-19. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1959-1968.	3.0	301
18	Ask and It Shall Be Given. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 594-596.	2.2	0

#	ARTICLE	IF	CITATIONS
19	Pilot Study of Return of Genetic Results to Patients in Adult Nephrology. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 651-664.	2.2	28
20	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. <i>Nature Communications</i> , 2020, 11, 1600.	5.8	120
21	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. <i>Kidney International Reports</i> , 2020, 5, 860-871.	0.4	2
22	Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. <i>Kidney International Reports</i> , 2020, 5, 940-945.	0.4	182
23	How COVID-19 Has Changed the Management of Glomerular Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 876-879.	2.2	23
24	Glomerular Diseases in Patients with Diabetes Mellitus: An Underappreciated Epidemic. <i>Kidney360</i> , 2020, 1, 220-222.	0.9	9
25	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. <i>New England Journal of Medicine</i> , 2019, 381, 36-46.	13.9	324
26	A Case of Iatrogenic Dehydration. <i>American Journal of Kidney Diseases</i> , 2019, 74, A15-A18.	2.1	0
27	Health-related quality of life in glomerular disease. <i>Kidney International</i> , 2019, 95, 1209-1224.	2.6	38
28	Diagnostic Utility of Exome Sequencing for Kidney Disease. <i>New England Journal of Medicine</i> , 2019, 380, 142-151.	13.9	456
29	Kidney Transplantation in C3 Glomerulopathy: A Case Series. <i>American Journal of Kidney Diseases</i> , 2019, 73, 316-323.	2.1	48
30	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. <i>American Journal of Kidney Diseases</i> , 2019, 73, 218-229.	2.1	68
31	Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 406-413.	2.2	63
32	C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. <i>Kidney International</i> , 2018, 93, 977-985.	2.6	123
33	Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 310-318.	0.4	85
34	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. <i>Kidney International Reports</i> , 2018, 3, 1373-1384.	0.4	39
35	Whole-Exome Sequencing in Adults With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2018, 168, 100.	2.0	154
36	Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents. <i>American Journal of Nephrology</i> , 2017, 45, 99-106.	1.4	35

#	ARTICLE	IF	CITATIONS
37	Idiopathic Immune Complex Glomerulonephritis. , 2017, , 1-10.		0
38	A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. Journal of the American Society of Nephrology: JASN, 2017, 28, 1306-1313.	3.0	174
39	Does NGAL reduce costs? A cost analysis of urine NGAL (uNGAL) & serum creatinine (sCr) for acute kidney injury (AKI) diagnosis. PLoS ONE, 2017, 12, e0178091.	1.1	21
40	Mixed Cryoglobulinemia. , 2017, , 1-13.		0
41	Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity. Aids, 2015, 29, 941-946.	1.0	26
42	The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome. Frontiers in Pediatrics, 2015, 3, 78.	0.9	21
43	A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Nephron, 2015, 130, 159-168.	0.9	49
44	Predictors of outcome for severe IgA Nephropathy in a multi-ethnic U.S. cohort. Clinical Nephrology, 2015, 84 (2015), 145-155.	0.4	13
45	Lack of Serologic Evidence to Link IgA Nephropathy with Celiac Disease or Immune Reactivity to Gluten. PLoS ONE, 2014, 9, e94677.	1.1	25
46	Rituximab treatment for fibrillary glomerulonephritis. Nephrology Dialysis Transplantation, 2014, 29, 1925-1931.	0.4	47
47	Use of Bortezomib in Heavy-Chain Deposition Disease: Report of 3 Cases. American Journal of Kidney Diseases, 2014, 64, 123-127.	2.1	15
48	Glomerular Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 617-625.	2.2	28
49	Su1445 Lack of Serologic Evidence for an Association Between Gluten Sensitivity and IgA Nephropathy. Gastroenterology, 2014, 146, S-471.	0.6	0
50	Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis. Nephrology Dialysis Transplantation, 2013, 28, 1371-1376.	0.4	25
51	Impact of the National Institutes of Health Focal Segmental Glomerulosclerosis (NIH FSGS) clinical trial on the treatment of steroid-resistant FSGS. Nephrology Dialysis Transplantation, 2013, 28, 527-534.	0.4	8
52	Treatment of Idiopathic FSGS with Adrenocorticotrophic Hormone Gel. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 2072-2081.	2.2	86
53	Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 748-756.	2.2	295
54	Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. Journal of the American Society of Hypertension, 2012, 6, 338-345.	2.3	35

#	ARTICLE	IF	CITATIONS
55	Diagnostic and Prognostic Stratification in the Emergency Department Using Urinary Biomarkers of Nephron Damage. <i>Journal of the American College of Cardiology</i> , 2012, 59, 246-255.	1.2	306
56	Treatment of Resistant Glomerular Diseases with Adrenocorticotrophic Hormone Gel: A Prospective Trial. <i>American Journal of Nephrology</i> , 2012, 36, 58-67.	1.4	83
57	New and emerging treatments for lupus nephritis. <i>Dialysis and Transplantation</i> , 2011, 40, 67-71.	0.2	0
58	A 56-year-old woman with sarcoidosis and acute renal failure. <i>Kidney International</i> , 2008, 74, 817-821.	2.6	13
59	Sensitivity and Specificity of a Single Emergency Department Measurement of Urinary Neutrophil Gelatinase-Associated Lipocalin for Diagnosing Acute Kidney Injury. <i>Annals of Internal Medicine</i> , 2008, 148, 810.	2.0	597
60	Disentangling a Case of Glomerulonephritis with Fibrils. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 0, , CJN.00630122.	2.2	0